BridgeMD
Dopamine agonist treatment of non-functioning pituitary adenomas (NFPAs) – a randomized controlled trial
EU CTIS ID: 2023-510039-12-00
What this study is testing
The main objective of the study is to evaluate the effect of medical treatment with cabergoline in non-functioning pituitary adenomas.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- A previously untreated non-functioning pituitary macroadenoma (largest diameter ≥ 10 mm) with either demonstrated growth on repeated MRI scans or ≤ 2 mm distance to chiasma opticum OR a residual non-functioning pituitary adenoma after surgery (largest diameter ≥ 5 mm) that is either extrasellar and/or with documented growth after surgical treatment of a non-functioning pituitary macroadenoma
You likely can't join if
- 1. Clear indication for surgery at the time of inclusion 2. Previous radiation therapy 3. Pituitary surgery the last 6 months 4. Previous apoplexy/bleeding in the adenoma 5. Pregnancy or lactation 6. Contraindications for cabergoline treatment • Known cardiac valvular disease • Known pulmonal, pericardial or retroperitoneal fibrosis • Clinical significant liver insufficiency • Use of medications that interact with cabergoline 7. Unfit to participate due to any other reason
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.